Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
KaQRypfZSgYpvp1F
